Exhaled NO in asthma: still in touch or definitively out of bounds?

NO is a biologically active free radical synthesized by the oxidative conversion of l-arginine to l-citrulline by the enzymes NO synthases (NOS) in the presence of cofactors. NO is highly reactive, making its direct determination almost impossible in biological tissues. In the gaseous phase, however, NO is relatively stable. Thus, when NO is formed within lung parenchyma adjacent to an airway lumen, a portion escapes by diffusion into the airway gas where it can be detected in the exhaled breath. In the lungs, NO is generated from different cell types including mast cells, macrophages, endothelial cells, epithelial cells, and airway and vascular smooth muscle cells (1). Because many conditions can modify the production and clearance of NO in the respiratory tract, there is considerable inter-subject variability in exhaled breath NO concentration measurements (2). On one hand, levels of exhaled NO concentrations are increased by airway viral infections, by allergic rhinitis, and by intake of a nitrate-rich meals. On the other hand, exercise, tobacco smoking, coffee intake, and laboratory investigations such as spirometry, hyperresponsiveness tests, and sputum induction appear to reduce exhaled NO levels. In addition, a decrease in substrate bioavailability and an increased production of endogenous NOS inhibitors can decrease the amount of NO produced by the lungs. Once produced, NO bioavailability may be decreased when S-nitrosoglutathione reductase activity is increased or when NO reacts with superoxide anion (3). In patients with asthma, high levels of NO concentration are typically found in exhaled breath (4). This increased NO concentration is attributed to induction of type-2 NOS (NOS2) transcription in inflamed bronchial epithelial cells and in inflammatory cells of asthmatic airways. The magnitude of NO concentration in exhaled breath is believed to increase in proportion with bronchial wall inflammation or inducedsputum eosinophilia as well as with airway hyperresponsiveness. The induction of NOS-2 transcription is decreased by corticosteroids (5), and NO in exhaled breath can be reduced following treatment with systemic or inhaled corticosteroids. However, despite extensive investigation, defining the precise role of NO in asthma has proved challenging. NO may activate soluble guanylate cyclase in airway smooth muscle cells and therefore exert a protective function by counteracting the bronchoconstriction mediated by inflammatory mediators. By contrast, NO may have damaging effect when it reacts with superoxide anion to form the highly toxic peroxynitrite anion. The assessment of asthma control is pivotal to the evaluation of treatment response both in routine clinical practise and in randomized trials. Asthma control is defined as the extent to which the various manifestations of asthma have been reduced or removed by treatment. Evaluation of asthma control includes not only assessment of clinical features such as symptoms and lung function, but also estimation of the patient’s risk of future adverse outcomes (6). Inhaled corticosteroids (ICS) are the mainstay of treatment for chronic asthma. International guidelines recommend that doses of ICS should be maintained at the minimum dose that is required to effectively control asthma symptoms to prevent adverse effects. However, the doses necessary to achieve this goal vary considerably between different patients and among individual patients over time, and there is a need for an easy, effective, and safe method to guide dose titration (6). In this regard, there is considerable interest in the validation of noninvasive methods as an adjunct to clinical assessment of asthma control. Because of logistic and cost issues, measurement of NO concentration in exhaled breath has been considered a promising biomarker in primary care-based asthma studies. It has been established that exhaled NO should be collected during a vital capacity manoeuvre and that a strong inverse relationship exists between the exhaled concentration of NO and the expiratory flow (7). The plateau of NO concentration measured during exhalation at the constant flow rate of 50 ml/s, referred to as FENO, has been extensively studied as a potential noninvasive index of asthma control, to titrate the dose of, or predict the response to, corticosteroids. However, results from studies employing FENO have been inconsistent. Smith et al. demonstrated that adjunct of FENO measurement permits the same level of asthma control with a significantly lower ICS doses compared to clinical assessment alone (8). Pijnenburg et al. demonstrated a greater improvement in airway responsiveness among patients followed using FENO compared to matched controls (9). By contrast, Shaw et al. reported that FENO-managed patients had similar doses of ICS compared to controls, without additional clinical benefit (10). Fritsch et al. (11) and Szefler et al. (12) reported no difference in asthma symptoms, asthma exacerbations, and results of most pulmonary function tests between control patients and FENO-managed patients, but in both cases the FENO groups received higher doses of ICS. Several explanations have been proposed for these seemingly contradictory results. One reason may lie in the differences in study designs and in study populations. Another possible explanation relates to the choice of FENO itself to evaluate NO metabolism in the Allergy